Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Exclusion Criteria

• •Received systemic anticancer therapy within the previous 21 days
• •Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
• •Any condition requiring concurrent systemic immunosuppressive therapy
• •Known immunodeficiency disorders, either primary or acquired
• •Bone lesion with indication of surgery (part #1) ; especially in case of spinal compression.
• •Known leptomeningeal disease
• •Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• •Prior treatment with immune checkpoints inhibitors
• •Administration of a live, attenuated vaccine within 30 days prior to first dose of study drug
• •Long-term use of systemic corticosteroids (unless to a dose of 20mg of methylprednisolone)